NEXTBIOMEDICAL Co., Ltd.

389650KOSDAQMedical, precision and optical instruments

NEXTBIOMEDICAL Co., Ltd. (389650, KOSDAQ) reported KRW 16bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2023
202410-435945Separate
202516-1-05948Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023
2024-37.5%30%76.8%6.3%
2025-4.4%-1.9%81.2%-0.6%

Revenue moved 72.7% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 252bn
Close priceKRW 30,400
Listed shares8,277,286
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)81
Women52 (64.2%)
Average tenure3 years
Annual pay, menKRW 69,241,379
Annual pay, womenKRW 32,461,538
Pay ratio, women to men46.9%

Other companies in Medical, precision and optical instruments

102 listed companies file under this classification. Showing 12.

See the whole Medical, precision and optical instruments list →